Hansoh Pharmaceutical Group Company Limited
3692
Rang in Aktien
#906
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Aktienkurs
$4.40
Marktkapitalisierung
$26.66B
Veränderung (1 Tag)
8.32%
Veränderung (1 Jahr)
-6.19%
Land
CN
Handel Hansoh Pharmaceutical Group Company Limited (3692)
Kategorie
Healthcare
P/S-Verhältnis für Hansoh Pharmaceutical Group Company Limited (3692)
P/S-Verhältnis zum October 2026 TTM: 10.23
Laut den neuesten Finanzberichten und dem Aktienkurs von Hansoh Pharmaceutical Group Company Limited beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 10.23. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 8.86.
P/S-Verlauf für Hansoh Pharmaceutical Group Company Limited von 2016 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 10.23 | 30.26% |
| 2024 | 7.85 | -11.45% |
| 2023 | 8.86 | 7.29% |
| 2022 | 8.26 | -10.41% |
| 2021 | 9.22 | -56.89% |
| 2020 | 21.39 | 46.55% |
| 2019 | 14.60 | 15.43% |
| 2018 | 12.64 | -15.54% |
| 2017 | 14.97 | -18.32% |
| 2016 | 18.33 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -30.98% |
IN
|
